Results 151 to 160 of about 29,271 (207)

Have Fixed-Duration (FD) Regimens Delivered on Their Promise in Chronic Lymphocytic Leukemia and What Is the Future of FD Regimens? A Narrative Review. [PDF]

Adv Ther
Allan JN.
europepmc   +1 more source

TP53-aberrated CLL: is BTK inhibitor monotherapy enough? [PDF]

Blood Adv
Niemann CU.
europepmc   +1 more source

Move along, nothing to see here: Btk inhibitors stop platelets sticking to plaques [PDF]

, 2018
Busygina, Bye, Bye, Byrd, Jamasbi, Levade   +5 more
core   +1 more source

Real‑life diagnostic and therapeutic approach to CLL/SLL in tuscany: the 2025 consensus. [PDF]

Clin Exp Med
D'Amato M, Rapolla CM, Benedetti E, Bocchia M, Capochiani E, Carlomagno G, Ciofini S, Giachetti R, Maestrini G, Moretti S, Nasso D, Papini G, Pirrotta MT, Simonetti F, Santini S, Vannucchi A, Galimberti S, Sanna A.   +17 more
europepmc   +1 more source

Potential of small-molecule targeted drugs in combination with CAR-T cell therapy for hematologic lymphomas. [PDF]

Front Immunol
Tang W, Yu S.
europepmc   +1 more source

BTK Inhibition in Hematology: From CLL/SLL to Emerging Applications Across B-Cell and Immune Disorders. [PDF]

Biomolecules
Duminuco A, De Luca P, Stanzione G, Caruso LA, Lavenia G, Scarso S, Garibaldi B, Palumbo FE, Vetro C, Palumbo GA.   +9 more
europepmc   +1 more source

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: Phase 2 trial results [PDF]

, 2018
et al,, Stockerl-Goldstein, Keith E, Vij, Ravi   +2 more
core   +1 more source

Bruton Tyrosine Kinase Inhibitor Ibrutinib and Pericardial Tamponade: A Case Report. [PDF]

Cureus
Baptista M, Soares M, Lima R, Ferreira C, Gregório T.   +4 more
europepmc   +1 more source

First-line treatment for CLL in the era of targeted therapy. [PDF]

Blood Cancer J
Davids MS, Stilgenbauer S, Tam CS.
europepmc   +1 more source

Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer. [PDF]

Clin Cancer Res
Armstrong A, van der Plancke G, Nishiguchi S, Salas-Benito D, Bouffard AA, Goncalves S, Merce AT, Kelly C, Birocchi F, Park S, Leick MB, Horick N, Berger TR, Maus MV, Escobar G.   +14 more
europepmc   +1 more source